ESCITALOPRAM 5mg, 10mg y 20 mg

La opción inteligente para controlar
la depresión y la ansiedad

Menor incidencia de efectos adversos(3)

Excelente perfil de seguridad por su alta selectividad(2,4)

Única presentación de 5mg(7)

PLAN DE BENEFICIO AL PACIENTE que favorece en la adherencia y cumplimiento del Tx

5 mg
10 mg
20 mg
Comprimidos
RECUBIERTOS
Caja x30 compromidos
  1. Chen, F., Larsen, M. B., Sánchez, C., & Wiborg, O. (2005). The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neuropsychopharmacology, 15(2), 193-198. h-ttp-s:/-/doi-.org-/10.1016/j.euroneuro.2004.08.008
  2. Kennedy, S. H., Andersen, H. F., & Lam, R.W. (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Journal of Psychiatry & Neuroscience: JPN, 31(2), 122-131.
  3. Kennedy, S. H., Andersen, H. F., & Thase, M. E. (2009). Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current Medical Research and Opinion, 25(1), 161-175 h-ttp-s:/-/doi-.org-/10.1185/03007990802622726
  4. Mahajan, S., Tandon, V., Arora, M., Mahajan, A., & Kotwal, S. (2019). Comparative efficacy and safety of escitalopram versus desvenlafaxine in postmenopausal women with depression and anxiety: A randomized, open-label, comparative trial. Journal of Mid-Life Health, 10(3), 141-146. h-ttp-s:/-/doi-.org-/10.4103/jmh.JMH_139_18
  5. Thase, M. E., Larsen, K. G., Reines, E., & Kennedy, S. H. (2013). the cardiovascular safety profile of escitalopram. European Neuropsychopharmacology, 23(11), 1391-1400. h-ttp-s:/-/doi-.org-/10.1016/j.euroneuro.2013.05.011
  6. Khan, A., Bose, A., Alexopoulos, G. S., Gommoll, C., Li, D., & Gandhi, C. (2007). Double-Blind Comparison of Escitalopram and Deluxetine in the Acute Treatment of Major Depressive Disorder. Clinical Drug Investigation, 27(7), 481-492. h-ttp-s:/-/doi-.org-/10.2165/00044011-200727070-00005
  7. Última revisión IQVIA MAT SEP 2022
este material es exclusivo para profesionales de la salud y de uso exclusivo para el representante medico